MERCK & CO INC
SC TO-T/A, 2000-06-15
PHARMACEUTICAL PREPARATIONS
Previous: KOLLMORGEN CORP, SC 14D9/A, 2000-06-15
Next: MERCK & CO INC, SC TO-T/A, EX-99.(A)(1)(K), 2000-06-15



                     SECURITIES AND EXCHANGE COMMISSION
                           WASHINGTON, D.C. 20549

                        ----------------------------

                    AMENDMENT NO. 3 (FINAL AMENDMENT) OF
                                SCHEDULE TO
      Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the
                    Securities Exchange Act of 1934 AND
                      AMENDMENT NO. 3 TO SCHEDULE 13D
                 Under the Securities Exchange Act of 1934

                        ----------------------------

                      PROVANTAGE HEALTH SERVICES, INC.
                     (Name of Subject Company (Issuer))
                     MERCK & CO., INC. (OFFEROR PARENT)
                       PV ACQUISITION CORP. (OFFEROR)
            MERCK-MEDCO MANAGED CARE, L.L.C. (PARENT SUBSIDIARY)
Names of Filing Persons (identifying status as offeror, issuer or other person))

                        ----------------------------
                  Common Stock, Par Value $0.01 Per Share
                     (Including the Associated Rights)
                       (Title of Class of Securities)
                                743725 10 3
                   (CUSIP Number of Class of Securities)

                        ----------------------------

                              CELIA A. COLBERT
                            PV ACQUISITION CORP.
                           C/O MERCK & CO., INC.
                              ONE MERCK DRIVE
                    WHITEHOUSE STATION, NEW JERSEY 08889
                               (908) 423-1000
 (Name, address and telephone number of person authorized to receive notices
              and communications on behalf of filing persons)

                              WITH A COPY TO:
                         GARY P. COOPERSTEIN, ESQ.
                  FRIED, FRANK, HARRIS, SHRIVER & JACOBSON
                             ONE NEW YORK PLAZA
                          NEW YORK, NEW YORK 10004
                               (212) 859-8000

                         CALCULATION OF FILING FEE

-----------------------------------------------------------------------------
      Transaction Valuation:  *                    Amount of filing fee:
      $226,724,985                                       $45,345
-----------------------------------------------------------------------------

* For purposes of calculating fee only. This amount is based on a per share
offering price of $12.25 for 18,150,000 shares of common stock and for
options to purchase 358,162 options with strike prices lower than $12.25
that may become exercisable before or during a subsequent offer period, if
any. Pursuant to the Agreement and Plan of Merger, dated as of May 4, 2000,
by and among ProVantage Health Services, Inc. (the "Company"), Merck & Co.,
Inc. and PV Acquisition Corp. (together, the "Bidders"), the Company
represented to the Bidders that, as of such date, it had 18,150,000 shares
of common stock issued and outstanding and 873,309 shares of common stock
reserved for issuance upon exercise of outstanding stock options, none of
which are currently exercisable and all of which will become exercisable
before or during a subsequent offer period, if any. The amount of the
filing fee, calculated in accordance with Rule 0-11 under the Securities
Exchange Act of 1934, as amended, equals 1/50 of one percent of the
aggregate of the cash offered by the Bidder.

     [X] Check box if any part of the fee is offset as provided by Rule
     0-11(a)(2) and identify the filing with which the offsetting fee was
     previously paid. Identify the previous filing by registration
     statement number, or the Form or Schedule and the date of its filing.

     Amount Previously Paid:  $226,724,985
     Form or Registration No.:  Schedule TO; Amendments No. 1 and
                                No. 2 to Schedule TO
     Filing Party:  Merck & Co., Inc. and PV Acquisition Corp.
     Date Filed:  May 10, 2000

[ ]  Check the box if the filing relates solely to preliminary
     communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which
the statement relates:

     [X]   third-party offer subject to Rule 14d-1.

     [ ]   issuer tender offer subject to Rule 13e-4.

     [ ]   going-private transactions subject to Rule 13e-3.

     [X]   amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the
results of the tender offer: [X]
<PAGE>
                             SCHEDULE 13D

CUSIP No.  743725-10-3

1   NAME OF REPORTING PERSON
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

        MERCK & CO., INC.

2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)

                                                         (a)  [ ]
                                                         (b)  [ ]

3   SEC USE ONLY

4   SOURCE OF FUNDS (See instructions)

        WC

5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
    PURSUANT TO ITEMS 2(d) or 2(e)                           [ ]

6   CITIZENSHIP OR PLACE OF ORGANIZATION

        NEW JERSEY

  NUMBER OF      7  SOLE VOTING POWER

   SHARES               17,770,956

 BENEFICIALLY    8  SHARED VOTING POWER

OWNED BY EACH           -0-

 REPORTING       9  SOLE DISPOSITIVE POWER

PERSON WITH             17,770,956

                10  SHARED DISPOSITIVE POWER

                        -0-

11  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    17,770,956

12  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)             [ ]
    EXCLUDES CERTAIN SHARES (See instructions)

13  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    97.91

14  TYPE OF REPORTING PERSON (See instructions)

    CO
<PAGE>
                             SCHEDULE 13D

CUSIP No.  743725-10-3

1   NAME OF REPORTING PERSON
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

        MERCK-MEDCO MANAGED CARE, L.L.C.

2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)

                                                         (a)  [ ]
                                                         (b)  [ ]

3   SEC USE ONLY

4   SOURCE OF FUNDS (See instructions)

        AF

5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
    PURSUANT TO ITEMS 2(d) or 2(e)                           [ ]

6   CITIZENSHIP OR PLACE OF ORGANIZATION

        DELAWARE

  NUMBER OF      7  SOLE VOTING POWER

   SHARES               17,770,956

 BENEFICIALLY    8  SHARED VOTING POWER

OWNED BY EACH           -0-

 REPORTING       9  SOLE DISPOSITIVE POWER

PERSON WITH             17,770,956

                10  SHARED DISPOSITIVE POWER

                        -0-

11  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    17,770,956

12  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)             [ ]
    EXCLUDES CERTAIN SHARES (See instructions)

13  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    97.91

14  TYPE OF REPORTING PERSON (See instructions)

    OO
<PAGE>
                             SCHEDULE 13D

CUSIP No.  743725-10-3

1   NAME OF REPORTING PERSON
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

        PV ACQUISITION CORP.

2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)

                                                         (a)  [ ]
                                                         (b)  [ ]

3   SEC USE ONLY

4   SOURCE OF FUNDS (See instructions)

        AF

5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
    PURSUANT TO ITEMS 2(d) or 2(e)                           [ ]

6   CITIZENSHIP OR PLACE OF ORGANIZATION

        DELAWARE

  NUMBER OF      7  SOLE VOTING POWER

   SHARES               17,770,956

 BENEFICIALLY    8  SHARED VOTING POWER

OWNED BY EACH           -0-

 REPORTING       9  SOLE DISPOSITIVE POWER

PERSON WITH             17,770,956

                10  SHARED DISPOSITIVE POWER

                        -0-

11  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    17,770,956

12  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)             [ ]
    EXCLUDES CERTAIN SHARES (See instructions)

13  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    97.91

14  TYPE OF REPORTING PERSON (See instructions)

    CO
<PAGE>
     This Amendment No. 3, filed on June 15, 2000 to the Schedules TO and
13D filed on May 10, 2000, as amended by Amendments No. 1 and No. 2 to
those Schedules, relates to the offer by PV Acquisition Corp., a Delaware
corporation and indirect wholly owned subsidiary of Merck & Co., Inc., a
New Jersey corporation ("Parent"), to purchase all of the outstanding
shares of Common Stock, par value $0.01 per share (the "Shares"), of
ProVantage Health Services, Inc., a Delaware corporation (the "Company"),
at a price of $12.25 per Share, net to the seller in cash and without
interest thereon, on the terms and subject to the conditions set forth in
the Offer to Purchase, dated May 10, 2000, and the related Letter of
Transmittal.

     This amendment is the final amendment to the Schedule TO and is also
Amendment No. 3 to the Schedule 13D. The tender offer terminated at 12:00
midnight, New York City time, on Wednesday, June 14, 2000. A total of
approximately 17,770,956 Shares were properly tendered and not withdrawn
as of the termination of the tender offer (including 59,100 Shares
tendered by notice of guaranteed delivery). This represented approximately
97.91% of the issued and outstanding Shares of the Company.

ITEM 2.  SUBJECT COMPANY INFORMATION

     Item 2 is hereby amended to add the following information:

     Pursuant to applicable New York Stock Exchange (the "NYSE") rules, the
Company has requested that the NYSE halt trading in the Shares and begin
delisting procedures.

ITEM 12.  EXHIBITS

     Item 12 is hereby amended to add the following exhibit:

     (a)(1)(K) -Press Release issued by Parent on June 15, 2000.
<PAGE>
                                 SIGNATURES

     After due inquiry and to the best of the knowledge and belief of each
of the undersigned, each of the undersigned certifies that the information
set forth in this statement is true, complete and correct.

June 15, 2000

                                  MERCK & CO., INC.

                                  By: /s/ Judy C. Lewent
                                     -----------------------------------
                                     Name:  Judy C. Lewent
                                     Title: Senior Vice President and Chief
                                            Financial Officer

                                  PV ACQUISITION CORP.

                                  By: /s/ Judy C. Lewent
                                     -----------------------------------
                                     Name:  Judy C. Lewent
                                     Title: President

                                  MERCK-MEDCO MANAGED CARE, L.L.C.

                                  By: /s/ Richard T. Clark
                                     -----------------------------------
                                     Name:  Richard T. Clark
                                     Title: President
<PAGE>
                               EXHIBIT INDEX

         EXHIBIT

         (a)(1)(K) -Press Release issued by Parent on June 15, 2000.


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission